EE05441B1 - 5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad - Google Patents

5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad

Info

Publication number: EE05441B1
Authority: EE; Estonia
Prior art keywords: triazatetracyclo; pentaene; hexadeca; tartrate salts; tartrate
Prior art date: 2001-05-14

Application number

EEP200300556A

Other languages

English (en)

Estonian (et)

Inventor

Everett Bogle David

Robert Rose Peter

Robert Williams Glenn

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2002-04-26

Publication date

2011-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05441(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-26 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-04-15 Publication of EE200300556A publication Critical patent/EE200300556A/xx

2011-08-15 Publication of EE05441B1 publication Critical patent/EE05441B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)

EEP200300556A 2001-05-14 2002-04-26 5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad EE05441B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29086101P	2001-05-14	2001-05-14
PCT/IB2002/001437 WO2002092089A1 (en)	2001-05-14	2002-04-26	Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (2)

Publication Number	Publication Date
EE200300556A EE200300556A (et)	2004-04-15
EE05441B1 true EE05441B1 (et)	2011-08-15

Family

ID=23117845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300556A EE05441B1 (et)	2001-05-14	2002-04-26	5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad

Country Status (47)

Country	Link
US (2)	US6890927B2 (xx)
EP (1)	EP1392307B1 (xx)
JP (1)	JP3779682B2 (xx)
KR (1)	KR100551184B1 (xx)
CN (1)	CN100370987C (xx)
AP (1)	AP1473A (xx)
AR (1)	AR033635A1 (xx)
AT (1)	ATE302607T1 (xx)
AU (1)	AU2002253482B2 (xx)
BG (1)	BG66408B1 (xx)
BR (1)	BR0209605A (xx)
CA (1)	CA2447405C (xx)
CR (1)	CR7080A (xx)
CZ (1)	CZ304763B6 (xx)
DE (1)	DE60205742T2 (xx)
DK (1)	DK1392307T3 (xx)
DO (1)	DOP2002000392A (xx)
EA (1)	EA005528B1 (xx)
EC (2)	ECSP034849A (xx)
EE (1)	EE05441B1 (xx)
EG (1)	EG24228A (xx)
ES (1)	ES2246396T3 (xx)
GE (1)	GEP20053712B (xx)
GT (1)	GT200200084A (xx)
HR (1)	HRP20030910B1 (xx)
HU (1)	HU229867B1 (xx)
IL (2)	IL157933A0 (xx)
IS (1)	IS2217B (xx)
MA (1)	MA27020A1 (xx)
ME (1)	ME00466B (xx)
MX (1)	MXPA03010364A (xx)
MY (1)	MY127807A (xx)
NO (1)	NO326148B1 (xx)
NZ (1)	NZ528210A (xx)
OA (1)	OA12599A (xx)
PA (1)	PA8545101A1 (xx)
PE (1)	PE20021065A1 (xx)
PL (1)	PL214876B1 (xx)
PT (1)	PT1392307E (xx)
RS (1)	RS50814B (xx)
SI (1)	SI1392307T1 (xx)
SK (1)	SK287170B6 (xx)
TN (1)	TNSN03113A1 (xx)
TW (1)	TWI262078B (xx)
UA (1)	UA73422C2 (xx)
WO (1)	WO2002092089A1 (xx)
ZA (1)	ZA200307235B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9814592B1 (pt) *	1997-12-31	2010-06-01		composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
EP1448235B1 (en) *	2001-11-30	2007-03-14	Pfizer Products Inc.	Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
JP2006528237A (ja) *	2003-05-20	2006-12-14	ファイザー・プロダクツ・インク	バレニクリンの医薬組成物
WO2005061519A1 (en) *	2003-12-19	2005-07-07	Takeda San Diego, Inc.	Kinase inhibitors
WO2005105788A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
EP1763521A1 (en) *	2004-06-30	2007-03-21	Eli Lilly and Company	1- (indole-6-carbonyl-d-phenylglycinyl)-4- (l-methylpiperidin-4- yl) piperazine d-tartrate
US7550598B2 (en) *	2004-08-18	2009-06-23	Takeda Pharmaceutical Company Limited	Kinase inhibitors
JP2008516942A (ja) *	2004-10-15	2008-05-22	ファイザー・プロダクツ・インク	バレニクリンの鼻腔内、バッカル、舌下および肺送達のための組成物および方法
ATE479687T1 (de)	2004-10-15	2010-09-15	Takeda Pharmaceutical	Kinaseinhibitoren
JP2008531540A (ja) *	2005-02-24	2008-08-14	ファイザー・プロダクツ・インク	高純度置換キノキサリンの調製
US20110086086A1 (en) *	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
KR20070119037A (ko) *	2006-02-21	2007-12-18	테바 파마슈티컬 인더스트리즈 리미티드	아르모다피닐의 신규한 결정질 형태 및 이것의 제조 방법
GEP20135728B (en)	2006-10-09	2013-01-25	Takeda Pharmaceuticals Co	Kinase inhibitors
EP2223925A1 (en) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase inhibitors
RU2009116260A (ru) *	2006-11-09	2010-11-10	Пфайзер Продактс Инк. (Us)	Полиморфные модификации никотиновых промежуточных продуктов
US20090062257A1 (en) *	2007-08-29	2009-03-05	Protia, Llc	Deuterium-enriched varenicline
WO2009045488A2 (en) *	2007-10-02	2009-04-09	Teva Pharmaceutical Industries Ltd.	Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) *	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
EP2262780A4 (en) *	2008-03-06	2012-01-25	Reddys Lab Ltd Dr	TARTRATE OF VARENICLINE AMORPHOUS
WO2009109651A1 (en) *	2008-03-06	2009-09-11	Medichem, S.A.	SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
US9463190B2 (en)	2008-03-31	2016-10-11	University Of South Florida	Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2268639A2 (en)	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) *	2008-09-01	2011-06-22	Actavis Group PTC EHF	Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
US20120093887A1 (en)	2009-06-10	2012-04-19	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru)	2009-06-22	2013-11-20	Тева Фармасьютикал Индастриз Лтд.	Твердые формы солей варениклина и способы их получения
WO2011110954A1 (en)	2010-03-09	2011-09-15	Actavis Group Ptc Ehf	Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
KR101673979B1 (ko)	2012-04-13	2016-11-08	리안윤강 진강 해신 파머수티컬 코. 엘티디.	화합물 jk12a 및 그 제조
KR101663550B1 (ko) *	2014-06-11	2016-10-07	조선대학교산학협력단	주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko)	2016-11-22	2017-04-10	주식회사 한서켐	바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
WO2021222230A1 (en)	2020-04-28	2021-11-04	Oyster Point Pharma, Inc.	Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
KR20240038022A (ko)	2021-08-20	2024-03-22	비위트 파마슈티컬 컴퍼니 리미티드	니트로사민 불순물, 니트로사민 불순물 생성을 줄일 수 있는 바레니클린 약학 조성물 및 그 제조와 응용
KR20230068877A (ko)	2021-11-11	2023-05-18	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) *	2021-11-22	2023-05-09	浙江车头制药股份有限公司	一种酒石酸伐尼克兰晶型的制备方法
US20250134904A1 (en)	2021-12-23	2025-05-01	Medichem, S.A.	Solid pharmaceutical formulations of varenicline
EP4241775A1 (en)	2022-03-11	2023-09-13	Par Pharmaceutical, Inc.	Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en)	2022-03-11	2023-03-14	Par Pharmaceutical, Inc.	Varenicline compound and process of manufacture thereof
WO2023244574A1 (en)	2022-06-14	2023-12-21	Amygdala Neurosciences, Inc.	Aldh-2 inhibitor compounds and methods of use
EP4611896A1 (en)	2022-11-04	2025-09-10	Pfizer Inc.	Prodrugs of varenicline and compounds containing vulnerable amines
KR20240115109A (ko)	2023-01-18	2024-07-25	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물
IT202300003888A1 (it)	2023-03-03	2024-09-03	Dipharma Francis Srl	Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Varenicline formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471503A (en)	1967-05-05	1969-10-07	Mcneilab Inc	1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
BR9814592B1 (pt) *	1997-12-31	2010-06-01		composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CZ20011726A3 (cs) *	2000-05-26	2002-02-13	Pfizer Products Inc.	Způsob reakční krystalizace, který umoľňuje řídit velikost částic

2002
- 2002-04-26 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/me unknown
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 EP EP02722625A patent/EP1392307B1/en not_active Expired - Lifetime
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/en not_active Ceased
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 CA CA002447405A patent/CA2447405C/en not_active Expired - Lifetime
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko not_active Expired - Lifetime
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EG24228A (en)	2008-11-10
MY127807A (en)	2006-12-29
US7265119B2 (en)	2007-09-04
NZ528210A (en)	2005-04-29
YU86703A (sh)	2006-05-25
DOP2002000392A (es)	2002-11-15
DE60205742D1 (de)	2005-09-29
PE20021065A1 (es)	2002-11-21
CA2447405C (en)	2006-10-17
JP2004533446A (ja)	2004-11-04
GT200200084A (es)	2003-09-12
HK1062645A1 (en)	2004-11-19
IL157933A0 (en)	2004-03-28
IL157933A (en)	2013-07-31
HRP20030910A2 (en)	2004-02-29
WO2002092089A1 (en)	2002-11-21
BG66408B1 (bg)	2014-01-31
SK13362003A3 (en)	2004-11-03
EA200301121A1 (ru)	2004-02-26
TWI262078B (en)	2006-09-21
ES2246396T3 (es)	2006-02-16
TNSN03113A1 (fr)	2005-12-23
EE200300556A (et)	2004-04-15
ECSP034849A (es)	2003-12-24
JP3779682B2 (ja)	2006-05-31
HU229867B1 (en)	2014-10-28
CA2447405A1 (en)	2002-11-21
ME00466B (me)	2011-10-10
BG108343A (bg)	2004-12-30
KR20040010638A (ko)	2004-01-31
ECSP034850A (es)	2003-12-24
PL214876B1 (pl)	2013-09-30
US20050148591A1 (en)	2005-07-07
BR0209605A (pt)	2004-03-23
EP1392307A1 (en)	2004-03-03
EP1392307B1 (en)	2005-08-24
AR033635A1 (es)	2003-12-26
KR100551184B1 (ko)	2006-02-13
DK1392307T3 (da)	2005-11-07
GEP20053712B (en)	2005-12-26
MA27020A1 (fr)	2004-12-20
SI1392307T1 (sl)	2005-12-31
RS50814B (sr)	2010-08-31
HUP0304088A3 (en)	2011-11-28
ATE302607T1 (de)	2005-09-15
CR7080A (es)	2006-08-09
ZA200307235B (en)	2004-09-16
UA73422C2 (en)	2005-07-15
SK287170B6 (sk)	2010-02-08
PT1392307E (pt)	2005-11-30
HUP0304088A2 (hu)	2004-04-28
EA005528B1 (ru)	2005-04-28
HRP20030910B1 (hr)	2011-11-30
PL366551A1 (en)	2005-02-07
AP2002002523A0 (en)	2002-06-30
CN100370987C (zh)	2008-02-27
CN1509174A (zh)	2004-06-30
IS6957A (is)	2003-09-15
CZ20032916A3 (cs)	2004-09-15
NO326148B1 (no)	2008-10-06
CZ304763B6 (cs)	2014-10-01
OA12599A (en)	2006-06-08
DE60205742T2 (de)	2006-05-11
NO20035036L (no)	2003-11-13
MXPA03010364A (es)	2004-03-16
PA8545101A1 (es)	2003-09-05
IS2217B (is)	2007-03-15
NO20035036D0 (no)	2003-11-13
US6890927B2 (en)	2005-05-10
AP1473A (en)	2005-09-30
AU2002253482B2 (en)	2007-09-06
US20030166701A1 (en)	2003-09-04

Publication	Publication Date	Title
EE200300556A (et)	2004-04-15	5,8,14-triasatetratsüklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad
NO20041560L (no)	2004-05-11	1,6-nafthyridinderivater som antidiabetiske midler
PL370913A1 (en)	2005-05-30	Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
ZA200410015B (en)	2005-09-28	Pharmaceutical salts.
NO20043174L (no)	2004-07-26	Pyrido[2,1-a]isokinolinderivater som DPP-IV inhibitorer
EE200300557A (et)	2004-04-15	5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
MXPA03007623A (es)	2003-12-04	Derivado de piridopirimidina o naftiridina.
NO20014050D0 (no)	2001-08-20	1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
EP1262195A4 (en)	2003-05-21	VASOACTIVE AGENTS
NO20034529L (no)	2003-12-08	3,7-diazabicyklo(3,3,1) - formuleringer som anti-arytmi- forbindelser
ATE355060T1 (de)	2006-03-15	2-methoxymethyl-3-(3,4-dichlorophenyl)-8- azabicyclo (3.2.1)octantartrat-salze
NO20024502L (no)	2002-11-20	4-okso-1,4-dihydro-3-cinnolinkarboksamider som antivirale midler
ES1050374Y (es)	2002-07-16	Maquina pulidora perfeccionada.
ITRM20010151V0 (it)	2001-08-01	Macchina trincia-erba perfezionata.
ITVI990086A0 (it)	1999-05-04	Stanghetta flessibile, particolarmente per occhiali.
ES1049777Y (es)	2002-05-16	Disposicion cobertora de colchones perfeccionada..
ES1048424Y (es)	2001-12-16	Colgador perfeccionado.
ITTO20010054A0 (it)	2001-01-24	Dispositivo di supporto, particolarmente per arredamenti componibili.

Legal Events

Date	Code	Title	Description
2011-04-15	HC1A	Change of owner name

EE05441B1 - 5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=23117845

Family Applications (1)

Country Status (47)

Families Citing this family (47)

Family Cites Families (4)

Also Published As

Similar Documents

Legal Events

EE05441B1 - 5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=23117845

Family Applications (1)

Country Status (47)

Families Citing this family (47)

Family Cites Families (4)

Also Published As

Similar Documents

Legal Events

EE05441B1 - 5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad - Google Patents